Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2023

Gouda Mohamed A, Nelson Blessie E, Buschhorn Lars, Wahida Adam, Subbiah Vivek

Abstract excerpt

Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored, which ultimately led to therapeutics with pan-cancer efficacy. To date, five molecular biomarkers have obtained FDA tissue-agnostic approval for targeted therapies and immunotherapies. Those include BRAFV600E mutations, RET fusions, NTRK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Medical Oncology
Share to Microsatellite Instability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 37061987
DOI: 10.1158/1078-0432.CCR-23-0090
PMCID: PMC10390861

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.PMID 37061987Read ↗

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right GenomicsSemantic proximity Read ↗

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.Semantic proximity Read ↗

[Histology-agnostic tumor treatment - a farewell to tumor entities?]Semantic proximity Read ↗

Harnessing tumor-agnostic biomarkers for precision medicine in lymphoma.Semantic proximity Read ↗

Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted TherapiesSemantic proximity Read ↗

Precision Oncology: Targeting Genomic Alterations and Cancer Signaling with Integrative Multi-Omics, Deep Learning and Network Biology in Medical OncologySemantic proximity Read ↗

Advances in Personalized OncologySemantic proximity Read ↗

Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.Semantic proximity Read ↗

Emerging Tumor-Agnostic Molecular Targets.Semantic proximity Read ↗

Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.Semantic proximity Read ↗

Integrative omics analyses broaden treatment targets in human cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.